Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 2893 | 24.52 |
09:38 ET | 400 | 24.65 |
09:39 ET | 100 | 24.735 |
09:48 ET | 720 | 24.57 |
09:59 ET | 100 | 24.625 |
10:01 ET | 100 | 24.5147 |
10:10 ET | 300 | 24.38 |
10:15 ET | 400 | 24.4 |
10:19 ET | 1000 | 24.42 |
10:24 ET | 358 | 24.41 |
10:26 ET | 123 | 24.39 |
10:32 ET | 400 | 24.24 |
10:33 ET | 100 | 24.275 |
10:35 ET | 2300 | 24.395 |
10:37 ET | 928 | 24.46 |
10:42 ET | 100 | 24.425 |
10:44 ET | 100 | 24.52 |
10:48 ET | 648 | 24.49 |
10:53 ET | 200 | 24.575 |
11:00 ET | 800 | 24.605 |
11:08 ET | 100 | 24.62 |
11:09 ET | 100 | 24.65 |
11:11 ET | 200 | 24.63 |
11:26 ET | 100 | 24.43 |
11:31 ET | 100 | 24.53 |
11:33 ET | 200 | 24.405 |
11:40 ET | 175 | 24.3301 |
11:42 ET | 400 | 24.39 |
11:45 ET | 100 | 24.35 |
11:51 ET | 400 | 24.35 |
11:56 ET | 1050 | 24.4 |
11:58 ET | 1314 | 24.335 |
12:00 ET | 100 | 24.32 |
12:02 ET | 500 | 24.37 |
12:07 ET | 150 | 24.4235 |
12:09 ET | 100 | 24.45 |
12:23 ET | 100 | 24.475 |
12:25 ET | 1700 | 24.59 |
12:27 ET | 300 | 24.565 |
12:30 ET | 1300 | 24.57 |
12:32 ET | 1884 | 24.45 |
12:34 ET | 205 | 24.437 |
12:36 ET | 100 | 24.45 |
12:38 ET | 500 | 24.4 |
12:39 ET | 500 | 24.49 |
12:41 ET | 700 | 24.572 |
12:43 ET | 100 | 24.62 |
12:45 ET | 100 | 24.62 |
12:48 ET | 600 | 24.65 |
12:50 ET | 200 | 24.62 |
12:54 ET | 629 | 24.58 |
12:57 ET | 800 | 24.62 |
12:59 ET | 200 | 24.57 |
01:01 ET | 200 | 24.51 |
01:03 ET | 100 | 24.5 |
01:08 ET | 800 | 24.52 |
01:10 ET | 1100 | 24.49 |
01:14 ET | 100 | 24.51 |
01:15 ET | 500 | 24.5 |
01:17 ET | 670 | 24.56 |
01:21 ET | 210 | 24.575 |
01:28 ET | 400 | 24.53 |
01:30 ET | 300 | 24.45 |
01:32 ET | 269 | 24.463 |
01:33 ET | 100 | 24.465 |
01:39 ET | 100 | 24.39 |
01:42 ET | 100 | 24.37 |
01:46 ET | 400 | 24.46 |
01:48 ET | 500 | 24.485 |
01:50 ET | 200 | 24.44 |
02:04 ET | 600 | 24.46 |
02:06 ET | 100 | 24.43 |
02:15 ET | 100 | 24.41 |
02:18 ET | 300 | 24.39 |
02:22 ET | 300 | 24.43 |
02:26 ET | 100 | 24.465 |
02:33 ET | 800 | 24.43 |
02:38 ET | 100 | 24.45 |
02:42 ET | 200 | 24.465 |
02:44 ET | 800 | 24.47 |
02:47 ET | 100 | 24.455 |
02:51 ET | 300 | 24.48 |
02:54 ET | 100 | 24.5 |
03:00 ET | 200 | 24.51 |
03:02 ET | 500 | 24.5 |
03:05 ET | 200 | 24.48 |
03:07 ET | 1197 | 24.515 |
03:09 ET | 100 | 24.51 |
03:14 ET | 300 | 24.45 |
03:20 ET | 700 | 24.43 |
03:21 ET | 462 | 24.45 |
03:23 ET | 500 | 24.455 |
03:25 ET | 200 | 24.44 |
03:30 ET | 600 | 24.425 |
03:32 ET | 1200 | 24.49 |
03:34 ET | 986 | 24.44 |
03:36 ET | 300 | 24.445 |
03:39 ET | 100 | 24.46 |
03:41 ET | 100 | 24.49 |
03:43 ET | 1500 | 24.46 |
03:50 ET | 238 | 24.46 |
03:52 ET | 1722 | 24.46 |
03:54 ET | 1426 | 24.47 |
03:56 ET | 1822 | 24.45 |
03:57 ET | 2665 | 24.45 |
03:59 ET | 30819 | 24.48 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.7B | -136.9x | --- |
CareDx Inc | 1.6B | -10.3x | --- |
Maravai LifeSciences Holdings Inc | 2.0B | -7.9x | --- |
MannKind Corp | 1.8B | 180.9x | --- |
Dynavax Technologies Corp | 1.4B | 109.0x | --- |
BioCryst Pharmaceuticals Inc | 1.6B | -10.4x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
---|---|
Revenue (TTM) | $338.9M |
Shares Outstanding | 71.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.34 |
EPS | $-0.18 |
Book Value | $6.23 |
P/E Ratio | -136.9x |
Price/Sales (TTM) | 5.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.